BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Brain cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
247 results:

  • 1. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.
    Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C
    ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. B7-H3 Expression in Breast cancer and brain Metastasis.
    Joshi V; Beecher K; Lim M; Stacey A; Feng Y; Jat PS; Duijf PHG; Simpson PT; Lakhani SR; McCart Reed AE
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612786
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Identification of genetic modifiers enhancing B7-H3-targeting car T cell therapy against glioblastoma through large-scale CRISPRi screening.
    Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
    J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. CD19 car-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.
    Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS
    Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Glioblastoma Therapy: Past, Present and Future.
    Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Decoding of the surfaceome and endocytome in primary glioblastoma cells identifies potential target antigens in the hypoxic tumor niche.
    de Oliveira KG; Bång-Rudenstam A; Beyer S; Boukredine A; Talbot H; Governa V; Johansson MC; Månsson AS; Forsberg-Nilsson K; Bengzon J; Malmström J; Welinder C; Belting M
    Acta Neuropathol Commun; 2024 Feb; 12(1):35. PubMed ID: 38414005
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The role of microbial metabolites in endocrine tumorigenesis: From the mechanistic insights to potential therapeutic biomarkers.
    Zhang Y; Tang N; Zhou H; Zhu Y
    Biomed Pharmacother; 2024 Mar; 172():116218. PubMed ID: 38308969
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Clinical features of neurotoxicity after CD19 car T-cell therapy in mantle cell lymphoma.
    Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
    Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Cocaine regulates antiretroviral therapy CNS access through pregnane-x receptor-mediated drug transporter and metabolizing enzyme modulation at the blood brain barrier.
    Colón Ortiz R; Knerler S; Fridman LB; Mercado A; Price AS; Rosado-Franco JJ; Wilkins H; Flores BR; Orsburn BC; Williams DW
    Fluids Barriers CNS; 2024 Jan; 21(1):5. PubMed ID: 38200564
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
    Ren X; Zhang G; Li G; Wang Y
    BMC Cancer; 2024 Jan; 24(1):10. PubMed ID: 38166723
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities.
    Zhou D; Gong Z; Wu D; Ma C; Hou L; Niu X; Xu T
    J Hematol Oncol; 2023 Dec; 16(1):121. PubMed ID: 38104104
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.
    Maccari M; Baek C; Caccese M; Mandruzzato S; Fiorentino A; Internò V; Bosio A; Cerretti G; Padovan M; Idbaih A; Lombardi G
    Oncologist; 2024 Apr; 29(4):289-302. PubMed ID: 38048782
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Immunity in malignant brain tumors: Tumor entities, role of immunotherapy, and specific contribution of myeloid cells to the brain tumor microenvironment.
    Kienzler JC; Becher B
    Eur J Immunol; 2024 Feb; 54(2):e2250257. PubMed ID: 37940552
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma.
    Gardam B; Gargett T; Brown MP; Ebert LM
    Front Immunol; 2023; 14():1261257. PubMed ID: 37928547
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [New treatment strategies for primary lymphoma of the central nervous system].
    Seidel S; Kaulen L; von Baumgarten L
    Nervenarzt; 2024 Feb; 95(2):117-124. PubMed ID: 37910181
    [TBL] [Abstract] [Full Text] [Related]  

  • 16.
    Hunger J; Schregel K; Boztepe B; Agardy DA; Turco V; Karimian-Jazi K; Weidenfeld I; Streibel Y; Fischer M; Sturm V; Santarella-Mellwig R; Kilian M; Jähne K; Sahm K; Wick W; Bunse L; Heiland S; Bunse T; Bendszus M; Platten M; Breckwoldt MO
    Theranostics; 2023; 13(15):5170-5182. PubMed ID: 37908732
    [No Abstract]    [Full Text] [Related]  

  • 17. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.
    Zhang HY; Yu HY; Zhao GX; Jiang XZ; Gao G; Wei BJ
    Front Endocrinol (Lausanne); 2023; 14():1273634. PubMed ID: 37867521
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress.
    Dewdney B; Jenkins MR; Best SA; Freytag S; Prasad K; Holst J; Endersby R; Johns TG
    Signal Transduct Target Ther; 2023 Oct; 8(1):400. PubMed ID: 37857607
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.
    Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdaisat S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Gregory Sawyer W
    Acta Biomater; 2023 Dec; 172():466-479. PubMed ID: 37788737
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 13.